DKDale Daniel Kim

Dale Daniel Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dale Daniel Kim has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Impact of Beers Criteria Medications in Elderly Patients With Head and Neck Cancer

    by Maxwell Y. Lee, Mason M. Sakamoto, Dale Kim, Andrey Finegersh, Vasu Divi, Rosh K. V. Sethi, Michelle M. Chen

    Background: Head and neck cancer patients often experience polypharmacy due to complex treatments and comorbidities. The Beers Criteria is a list of potentially inappropriate medications (PIMs) for patients above age 65 developed by the American Geriatrics Society. We hypothesize that increased use of PIMs will be associated with inferior health and quality of life outcomes in elderly patients with head and neck cancer. Methods: We retrospectively examined patients aged ≥ 65 years with head and neck cancer diagnosed between 2011 and 2015 using SEER‐Medicare data, analyzing associations between Beers Criteria Medications (BCMs) and survival as a primary outcome. Emergency department (ED) utilization served as a secondary outcome. Results: Among 5213 patients (mean age 72.6 years), 44% received no BCMs within 1 year of diagnosis, while 41.3% received 1 BCM, 9.3% received 2 BCMs, and 5.4% received ≥ 3 BCMs. The most common medications prescribed were Lorazepam (12.3%), Zolpidem (7.9%), and Alprazolam (7.5%). Two‐year survival decreased with BCM use in a dose‐dependent fashion: 88.2% (0 BCM), 86.8% (1 BCM), 86.7% (2 BCMs), and 81.4% (≥ 3 BCMs; p < 0.001). BCM users had higher ED utilization in the year after diagnosis (mean 1.21 vs. 0.95 claims, p = 0.004). Conclusions: BCMs in elderly head and neck cancer patients were associated with inferior survival and increased healthcare utilization. These findings highlight the need for medication reconciliation and systematic reviews by multidisciplinary care teams to optimize outcomes in this vulnerable population.

  • Open Access

    Predicting Rejection Risk in Heart Transplantation: An Integrated Clinical–Histopathologic Framework for Personalized Post-Transplant Care

    by Dale D. Kim, Anant Madabhushi, Kenneth B. Margulies, Eliot G. Peyster

    Background: Cardiac allograft rejection (CAR) remains the leading cause of early graft failure after heart transplantation (HT). Current diagnostics, including histologic grading of endomyocardial biopsy (EMB) and blood-based assays, lack accurate predictive power for future CAR risk. We developed a predictive model integrating routine clinical data with quantitative morphologic features extracted from routine EMBs to demonstrate the precision-medicine potential of mining existing data sources in post-HT care. Methods: In a retrospective cohort of 484 HT recipients with 1,188 EMB encounters within 6 months post-transplant, we extracted 370 quantitative pathology features describing lymphocyte infiltration and stromal architecture from digitized H&E-stained slides. Longitudinal clinical data comprising 268 variables—including lab values, immunosuppression records, and prior rejection history—were aggregated per patient. Using the XGBoost algorithm with rigorous cross-validation, we compared models based on four different data sources: clinical-only, morphology-only, cross-sectional-only, and fully integrated longitudinal data. The top predictors informed the derivation of a simplified Integrated Rejection Risk Index (IRRI), which relies on just 4 clinical and 4 morphology risk facts. Model performance was evaluated by AUROC, AUPRC, and time-to-event hazard ratios. Results: The fully integrated longitudinal model achieved superior predictive accuracy (AUROC 0.86, AUPRC 0.74). IRRI stratified patients into risk categories with distinct future CAR hazards: high-risk patients showed a markedly increased CAR risk (HR=6.15, 95% CI: 4.17–9.09), while low-risk patients had significantly reduced risk (HR=0.52, 95% CI: 0.33–0.84). This performance exceeded models based on just cross-sectional or single-domain data, demonstrating the value of multi-modal, temporal data integration. Conclusions: By integrating longitudinal clinical and biopsy morphologic features, IRRI provides a scalable, interpretable tool for proactive CAR risk assessment. This precision-based approach could support risk-adaptive surveillance and immunosuppression management strategies, offering a promising pathway toward safer, more personalized post-HT care with the potential to reduce unnecessary procedures and improve outcomes. Clinical Perspective: What is new? Current tools for cardiac allograft monitoring detect rejection only after it occurs and are not designed to forecast future risk. This leads to missed opportunities for early intervention, avoidable patient injury, unnecessary testing, and inefficiencies in care. We developed a machine learning–based risk index that integrates clinical features, quantitative biopsy morphology, and longitudinal temporal trends to create a robust predictive framework. The Integrated Rejection Risk Index (IRRI) provides highly accurate prediction of future allograft rejection, identifying both high- and low-risk patients up to 90 days in advance – a capability entirely absent from current transplant management. What are the clinical implications? Integrating quantitative histopathology with clinical data provides a more precise, individualized estimate of rejection risk in heart transplant recipients. This framework has the potential to guide post-transplant surveillance intensity, immunosuppressive management, and patient counseling. Automated biopsy analysis could be incorporated into digital pathology workflows, enabling scalable, multicenter application in real-world transplant care.


  • Effects of diagnostic delays in head and neck cancer patients presenting to the emergency department

    by Maxwell Y. Lee, Jeffrey D. Huynh, Dale D. Kim, John B. Sunwoo, Michelle M. Chen


  • Open Access

    Understanding Reasons for Oral Anticoagulation Nonprescription in Atrial Fibrillation Using Large Language Models

    by Sulaiman Somani, Dale Daniel Kim, Eduardo Perez‐Guerrero, Summer Ngo, Tina Seto, Sadeer Al‐Kindi, Tina Hernandez‐Boussard, Fatima Rodriguez

    Background: Rates of oral anticoagulation (OAC) nonprescription in atrial fibrillation approach 50%. Understanding reasons for OAC nonprescription may reduce gaps in guideline‐recommended care. We aimed to identify reasons for OAC nonprescription from clinical notes using large language models. Methods: We identified all patients and associated clinical notes in our health care system with a clinician‐billed visit for atrial fibrillation without another indication for OAC and stratified them on the basis of active OAC prescriptions. Three annotators labeled reasons for OAC nonprescription in clinical notes on 10% of all patients (“annotation set”). We engineered prompts for a generative large language model (Generative Pre‐trained Transformer 4) and trained a discriminative large language model (ClinicalBERT) to identify reasons for OAC nonprescription and selected the best‐performing model to predict reasons for the remaining 90% of patients (“inference set”). Results: A total of 35 737 patients were identified, of which 7712 (21.6%) did not have active OAC prescriptions. A total of 910 notes across 771 patients were annotated. Generative Pre‐trained Transformer 4 outperformed ClinicalBERT (macro‐F1 score across all reasons of 0.79, compared with 0.69 for ClinicalBERT). Using Generative Pre‐trained Transformer 4 on the inference set, 61.1% of notes had documented reasons for OAC nonprescription, most commonly the alternative use of an antiplatelet agent (23.3%), therapeutic inertia (21.0%), and low burden of atrial fibrillation (17.1%). Conclusions: This is the first study using large language models to extract documented reasons for OAC nonprescription from clinical notes in patients with atrial fibrillation and reveals guideline‐discordant practices and actionable insights for the development of health system interventions to reduce OAC nonprescription.


  • Granzyme F: Exhaustion Marker and Modulator of Chimeric Antigen Receptor T Cell–Mediated Cytotoxicity

    by Zachary L. Z. Hay, Dale D. Kim, Jennifer M. Cimons, Jennifer R. Knapp, M. Eric Kohler, Mary Quansah, Tiffany M. Zúñiga, Faye A Camp, Mayumi Fujita, Xiao-Jing Wang, et al.

    Granzymes are a family of proteases used by CD8 T cells to mediate cytotoxicity and other less-defined activities. The substrate and mechanism of action of many granzymes are unknown, although they diverge among the family members. In this study, we show that mouse CD8+ tumor-infiltrating lymphocytes (TILs) express a unique array of granzymes relative to CD8 T cells outside the tumor microenvironment in multiple tumor models. Granzyme F was one of the most highly upregulated genes in TILs and was exclusively detected in PD1/TIM3 double-positive CD8 TILs. To determine the function of granzyme F and to improve the cytotoxic response to leukemia, we constructed chimeric Ag receptor T cells to overexpress a single granzyme, granzyme F or the better-characterized granzyme A or B. Using these doubly recombinant T cells, we demonstrated that granzyme F expression improved T cell–mediated cytotoxicity against target leukemia cells and induced a form of cell death other than chimeric Ag receptor T cells expressing only endogenous granzymes or exogenous granzyme A or B. However, increasing expression of granzyme F also had a detrimental impact on the viability of the host T cells, decreasing their persistence in circulation in vivo. These results suggest a unique role for granzyme F as a marker of terminally differentiated CD8 T cells with increased cytotoxicity, but also increased self-directed cytotoxicity, suggesting a potential mechanism for the end of the terminal exhaustion pathway.


  • Open Access

    c-Myc uses Cul4b to preserve genome integrity and promote antiviral CD8+ T cell immunity

    by Asif A. Dar, Dale D. Kim, Scott M. Gordon, Kathleen Klinzing, Siera Rosen, Ipsita Guha, Nadia Porter, Yohaniz Ortega, Katherine S. Forsyth, Jennifer Roof, et al.

    During infection, virus-specific CD8+ T cells undergo rapid bursts of proliferation and differentiate into effector cells that kill virus-infected cells and reduce viral load. This rapid clonal expansion can put T cells at significant risk for replication-induced DNA damage. Here, we find that c-Myc links CD8+ T cell expansion to DNA damage response pathways though the E3 ubiquitin ligase, Cullin 4b (Cul4b). Following activation, c-Myc increases the levels of Cul4b and other members of the Cullin RING Ligase 4 (CRL4) complex. Despite expressing c-Myc at high levels, Cul4b-deficient CD8+ T cells do not expand and clear the Armstrong strain of lymphocytic choriomeningitis virus (LCMV) in vivo. Cul4b-deficient CD8+ T cells accrue DNA damage and succumb to proliferative catastrophe early after antigen encounter. Mechanistically, Cul4b knockout induces an accumulation of p21 and Cyclin E2, resulting in replication stress. Our data show that c-Myc supports cell proliferation by maintaining genome stability via Cul4b, thereby directly coupling these two interdependent pathways. These data clarify how CD8+ T cells use c-Myc and Cul4b to sustain their potential for extraordinary population expansion, longevity and antiviral responses.


  • Open Access

    The ubiquitin ligase Cul5 regulates CD4+ T cell fate choice and allergic inflammation

    by Binod Kumar, Natania S. Field, Dale D. Kim, Asif A. Dar, Yanqun Chen, Aishwarya Suresh, Christopher F. Pastore, Li-Yin Hung, Nadia Porter, Keisuke Sawada, et al.

    Antigen encounter directs CD4+ T cells to differentiate into T helper or regulatory cells. This process focuses the immune response on the invading pathogen and limits tissue damage. Mechanisms that govern T helper cell versus T regulatory cell fate remain poorly understood. Here, we show that the E3 ubiquitin ligase Cul5 determines fate selection in CD4+ T cells by regulating IL-4 receptor signaling. Mice lacking Cul5 in T cells develop Th2 and Th9 inflammation and show pathophysiological features of atopic asthma. Following T cell activation, Cul5 forms a complex with CIS and pJak1. Cul5 deletion reduces ubiquitination and subsequent degradation of pJak1, leading to an increase in pJak1 and pSTAT6 levels and reducing the threshold of IL-4 receptor signaling. As a consequence, Cul5 deficient CD4+ T cells deviate from Treg to Th9 differentiation in low IL-4 conditions. These data support the notion that Cul5 promotes a tolerogenic T cell fate choice and reduces susceptibility to allergic asthma.